Key Insights on Gross Profit: AstraZeneca PLC vs Exelixis, Inc.

AstraZeneca PLC vs Exelixis, Inc.: A Decade of Gross Profit Trends

In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Exelixis, Inc. have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, AstraZeneca's gross profit surged by approximately 86%, reflecting its robust market strategies and product innovations. In contrast, Exelixis, Inc. experienced a remarkable growth of over 7,500%, albeit from a much smaller base, highlighting its rapid expansion and increasing market presence.

Key Insights

• AstraZeneca's Growth: Starting at around $20 billion in 2014, AstraZeneca's gross profit reached nearly $38 billion by 2023, underscoring its consistent growth.
• Exelixis's Expansion: Despite starting with a modest $23 million in 2014, Exelixis's gross profit climbed to approximately $1.76 billion in 2023, marking its emergence as a significant player.

These trends reflect the dynamic nature of the pharmaceutical sector, where strategic innovation and market adaptation are key to success.